drugset / Trial / NCT06501963

Revealing Protective Immunity to Influenza Using Systems Immunology

NCT06501963

Phase 4 Completed 51 enrolled Emory University Boston University · collab
NaSingle-groupOpen-labelBasic science

Summary

The goals of this study are to better understand the human immune response to influenza vaccines, specifically the live attenuated (weakened) influenza vaccine given as a nasal spray. Better understanding why this vaccine does not work as well in adults as it does in children may help design better influenza vaccines.

Timeline

Start
2024-10-14
Primary completion
2025-04-01
Completion
2025-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject FluMist Vaccine 0.2 ml Intranasal

Indications